复发转移性结直肠癌FOLFOXIRI方案一线治疗的临床观察  

FOLFOXIRI regimen in first-line treatment of refractory and metastatic colorectal cancer

作　　者：李玉芳[1] 陈敏斌[1] 沈文香[1] 王李强[1] 陈长广[1] 傅爱林[1] 杨蕴[1] 

机构地区：[1]昆山市第一人民医院肿瘤科,江苏昆山215300

出　　处：《中华肿瘤防治杂志》2010年第21期1771-1773,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨FOLFOXIRI方案〔伊立替康(CPT-11)+奥沙利铂(L-OHP)+5-氟尿嘧啶(5-FU)+甲酰四氢叶酸(LV)〕一线治疗复发或转移性结直肠癌的临床疗效和安全性。方法:对46例复发或转移性结直肠癌患者,采用FOLFO-XIRI方案治疗。CPT-11 150 mg/m2,持续静脉滴入90 min,d1;L-OHP 65 mg/m2,持续静脉滴入2 h,d2;LV200 mg/m2,持续静脉滴入2 h,d2;5-FU 400 mg/m2,静脉推注,d2,d3;5-FU600 mg/m2持续静脉滴入22 h(泵),d2,d3;每14 d重复。观察近期疗效及不良反应。结果:46例患者中,完全缓解(CR)2例(4.3%),部分缓解(PR)25例(54.3%),稳定(SD)14例(30.4%),疾病进展(PD)6例(10.9%)。未手术的患者中位疾病进展时间(TTP)10.2个月。安全性评价:发生率最高的Ⅲ、Ⅳ度毒副反应是中性粒细胞减少13例(28.0%),腹泻6例(13.0%)。结论:FOLFOXIRI方案一线治疗复发或转移性结直肠癌安全、有效。OBJECTIVE：To evaluate the efficacy and safety of first line chemotherapy：irinotecan（CPT-11）＋oxaliplatin（L-OHP） ＋ 5-fluorouracil（5-FU） and leucovorin（LV）（FOLFOXIRI regimen）,for the patients with refractory and metastatic colorectal cancer.METHODS：Forty-six patients with metastatic and refractory colorectal cancer were enrolled into this prospective study.The patients were given with CPT-11（150 mg/m2,30 min of iv.drip,d1）,L-OHP（65 mg/m2,2 h of iv.drip,d2）;LV（200 mg/m2,2 h of iv.drip,d2） and 5-FU（400 mg/m2,iv bolus;and then,600 mg/m2 as a 22 h continuous iv.drip,d2,d3） every 2 weeks.RESULTS：There were 2（4.3%）CR patients,25（54.3%） PR patients,14 SD（30.4%） and 6 PD（10.9%）.The adverse events：The highest rates of Ⅲ and Ⅳ degree adverse events were leucopenia（28.0%） and diarrhea（13.0%）.TTP of the unresectable patients was 10.2 months.CONCLUSION：The FOLFOXIRI regimen is effective and well-tolerated as a first-line chemotherapy for the patients with refractory or metastatic colorectal cancer.

关 键 词：结直肠肿瘤/药物疗法 抗肿瘤药/治疗应用 肿瘤复发 局部 治疗结果 

分 类 号：R735.3[医药卫生—肿瘤]